Infliximab maintains durable response and facilitates catch-up growth In luminal pediatric Crohn's disease

Keyphrases

• Durable Response 100%
• Catch-up Growth 100%
• Infliximab 100%
• Pediatric Crohn's Disease 100%
• Crohn's Disease 83%
• Clinical Response 33%
• Immunomodulation 33%
• Linear Growth 33%
• Height-for-age Z-score 33%
• Mean Height 33%
• Antibodies to Infliximab 33%
• Loss of Response 33%
• Durability of Response 33%
• First Year 16%
• Disease Duration 16%
• Clinical Remission 16%
• Complete Resolution 16%
• Confidence Interval 16%
• Hazard Ratio 16%
• Cox Proportional Hazards Model 16%
• Pediatric 16%
• Female Gender 16%
• Endoscopic Diagnosis 16%
• Low Response 16%
• Mucosal Ulcers 16%
• Dose Escalation 16%
• Immunomodulator 16%
• Growth Potential 16%
• Mucosal Healing 16%
• Tanner 16%
• Pediatric Crohn's Disease Activity Index 16%
• Complete Response 16%
• Complete Responders 16%
• Physician Global Assessment 16%
• Global Pediatrics 16%

Medicine and Dentistry

• Pediatrics 100%
• Catch up Growth 100%
• Crohn's Disease 100%
• Infliximab 100%
• Immunomodulation 25%
• Disease Duration 12%
• Adolescent 12%
• Hazard Ratio 12%
• Proportional Hazards Model 12%
• Venous Ulcer 12%
• Immunomodulating Agent 12%
• Crohn's Disease Activity Index 12%

Immunology and Microbiology

• Crohn's Disease 100%
• Catch up Growth 100%
• Infliximab 100%
• Monospecific Antibody 37%
• Immunomodulation 25%
• Immunomodulating Drugs 12%